Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Overview 6 Therapeutics Development 7 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Stage of Development 7 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Therapy Area 8 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Indication 9 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Companies 12 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Companies Involved in Therapeutics Development 19 Celtaxsys, Inc. 19 Johnson & Johnson 20 Nippon Kayaku Co., Ltd. 21 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Drug Profiles 22 acebilustat - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 CTX-3397 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CTX-3421 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 EDO-66 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 JNJ-26993135 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 ubenimex - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Dormant Projects 32 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Featured News & Press Releases 33 Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema 33 Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 33 May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis 34 Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency 35 Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension 35 Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary 35 Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis 36 Oct 01, 2015: Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients 36 Jul 06, 2015: Celtaxsys Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis 37 Jun 10, 2015: Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF 38 Jun 02, 2015: Celtaxsys Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial 38 Apr 07, 2015: Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately 39 Feb 03, 2015: Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA 40 Oct 30, 2014: Celtaxsys’ Cystic Fibrosis Therapy Receives Positive Opinion In EU 40 Oct 10, 2013: Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016’, provides in depth analysis on Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted pipeline therapeutics. The report provides comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - The report reviews Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics and enlists all their major and minor projects - The report assesses Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeTable of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Overview 6 Therapeutics Development 7 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Stage of Development 7 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Therapy Area 8 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Indication 9 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Products under Development by Companies 12 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Companies Involved in Therapeutics Development 19 Celtaxsys, Inc. 19 Johnson & Johnson 20 Nippon Kayaku Co., Ltd. 21 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Drug Profiles 22 acebilustat - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 CTX-3397 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CTX-3421 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 EDO-66 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 JNJ-26993135 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 ubenimex - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Dormant Projects 32 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Featured News & Press Releases 33 Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema 33 Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 33 May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis 34 Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency 35 Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension 35 Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary 35 Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis 36 Oct 01, 2015: Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients 36 Jul 06, 2015: Celtaxsys Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis 37 Jun 10, 2015: Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF 38 Jun 02, 2015: Celtaxsys Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial 38 Apr 07, 2015: Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately 39 Feb 03, 2015: Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA 40 Oct 30, 2014: Celtaxsys’ Cystic Fibrosis Therapy Receives Positive Opinion In EU 40 Oct 10, 2013: Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43

Celtaxsys, Inc. Johnson & Johnson Nippon Kayaku Co., Ltd.